Echo Therapeutics To Present Positive Clinical Trial Results At The 14th Annual Diabetes Technology Meeting
PHILADELPHIA, Nov. 3, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"), a medical device company, will present its most recently completed clinical study of its non-invasive Symphony® Continuous Glucose Monitoring (CGM) System at the 14th Annual Diabetes Technology Meeting, November 6th to 8th in Bethesda, MD.
The study's Principal Investigator, Jeffrey I. Joseph, D.O., Vice-Chairman and Director of Research, Department of Anesthesiology and Director of the Artificial Pancreas Center at Thomas Jefferson University in Philadelphia, PA, will present the findings during poster presentations on Thursday, November 6th, 4-6:30 p.m. ET. The poster, entitled "Non-Invasive Continuous Glucose Monitoring (CGM) in Post-Surgical Diabetic and Non-Diabetic Intensive Care Unit (ICU) Patients" (JOSE1459D), will provide an expanded analysis of data collected from the multi-center clinical trial of Echo's Symphony CGM System in post-surgical diabetic and non-diabetic patients in hospital intensive care units.
About Echo Therapeutics
Echo Therapeutics was developing its Symphony® CGM System as a non-invasive, wireless, continuous glucose monitoring system for use initially in the critical care setting. A significant longer-term opportunity may also exist for Symphony to be used in the hospital beyond the critical care settings, as well as in the outpatient setting. Echo also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.
Cautionary Statement Concerning Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current expectation and beliefs of Echo's management about the business of Echo. These forward-looking statements are subject to certain risks and uncertainties that could cause actual events to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, but are not limited to, risks related to the actions of Platinum Management (NY) LLC, its affiliates and the other members of its group, including, but not limited to, the lawsuits filed or threatened by the Platinum Group and the actions taken by the Platinum Group to harm Echo's prospects and interfere with Echo's relationships with its vendors and employees, including the amount of related costs and the disruption caused to business and financing activities by these actions, the potential inability of Echo to secure additional funding for its operations, the possibility that Echo may be forced to seek protection under the U.S. Bankruptcy Code, the adverse impact of any such bankruptcy filing by Echo on its business, financial condition and results of operations, including its ability to maintain relationships with vendors and employees, the actions of Echo's creditors and other third parties with interests in any bankruptcy case filed by Echo, and Echo's ability to obtain bankruptcy court approval in connection with any bankruptcy case filed by Echo. Other risks and uncertainties that may cause actual events to differ materially from the statements we have made herein are identified and described in more detail in Echo's filings with the SEC, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2013, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The forward-looking statements in this Press Release are made as of the date hereof. Notwithstanding changes that may occur with respect to matters relating to any forward looking statements, Echo does not expect to, and disclaims any obligation to, publicly update, amend or clarify any forward-looking statements whether as a result of new information, future events or otherwise. Echo, however, reserves the right to update such statements or any portion thereof at any time for any reason.
For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104
colimpio@echotx.com
Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx
SOURCE Echo Therapeutics, Inc.